Primary Pancreatic Lymphoma in Korea-A Single Center Experience.
10.3346/jkms.2010.25.4.536
- Author:
Won Jae YOON
1
;
Yong Bum YOON
;
Youn Joo KIM
;
Ji Kon RYU
;
Yong Tae KIM
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. yyb10604@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Pancreas;
Lymphoma
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Child;
Female;
Humans;
Korea;
Lymphoma/classification/diagnosis/*pathology/therapy;
Male;
Middle Aged;
Pancreatic Neoplasms/classification/diagnosis/*pathology/therapy;
Prognosis;
Retrospective Studies;
Treatment Outcome;
Young Adult
- From:Journal of Korean Medical Science
2010;25(4):536-540
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to report a single center experience of primary pancreatic lymphoma (PPL) in Korea. We analyzed the clinicopathological data from four PPL patients (three male, median age 36 yr) diagnosed from 1997 to 2007 at Seoul National University Hospital. The diagnoses were: diffuse large B cell lymphoma (n=2), Ki-1 (+) anaplastic large cell lymphoma (n=1), and Burkitt lymphoma (n=1). Presenting symptoms and signs were: abdominal pain (n=4), pancreatitis (n=2), weight loss (n=2) and abdominal mass (n=1). No patient underwent surgery. The Ann Arbor stages of the patients were: IEA (n=1), IIEA (n=1), and IVEB (n=2). Two patients underwent treatment. The stage IEA patient underwent chemotherapy and radiation therapy that resulted in a complete remission. The stage IVEB patient who underwent chemotherapy relapsed. This patient underwent subsequent peripheral blood stem cell transplantation and is alive at 30 months. Two patients (stages IVEB and IIEA) without treatment died at 0.8 and 7.0 months, respectively. For PPL patients, chemotherapy-based treatment, and addition of radiation therapy, if possible, may offer good prognosis.
